NO20022456L - Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon - Google Patents

Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon

Info

Publication number
NO20022456L
NO20022456L NO20022456A NO20022456A NO20022456L NO 20022456 L NO20022456 L NO 20022456L NO 20022456 A NO20022456 A NO 20022456A NO 20022456 A NO20022456 A NO 20022456A NO 20022456 L NO20022456 L NO 20022456L
Authority
NO
Norway
Prior art keywords
optionally substituted
alkyl
compounds
membered
group
Prior art date
Application number
NO20022456A
Other languages
English (en)
Other versions
NO20022456D0 (no
Inventor
Helen Jane Bryant
William Robert Carling
Mark Stuart Chambers
Sarah Christine Hobbs
Philip Jones
Angus Murray Macleod
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927874.9A external-priority patent/GB9927874D0/en
Priority claimed from GB0009602A external-priority patent/GB0009602D0/en
Priority claimed from GB0018651A external-priority patent/GB0018651D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NO20022456D0 publication Critical patent/NO20022456D0/no
Publication of NO20022456L publication Critical patent/NO20022456L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelser med formel (I), og salter derav, hvor R1 betegner halogen eller d-s-alkyl, C3_7-sykloalkyl, C4.7-sykloal- kenyl, C6-s-bisykloalkyl, C6-i0-aryl, C3.7- heterosykloalkyl, heteroaryl eller di- (d-s) alkylamino, idet en hvilken som helst av disse grupper eventuelt er substituert; L er O, S eller NR", hvor R" er H, d-e-alkyl eller C3-6-sykloalkyl; W er d-6-alkyl, d-«-alkenyl eller C2.s- alkynyl, hvilke eventuelt er substitu- ert; X er NR4R5, eller X er en 5-leddet eller 6-leddet heteroaromatisk ring som eventuelt er kondensert med en benzen- eller pyridinring og eventuelt er sub- stituert; Y er eventuelt forgrenet d-4- alkylen som eventuelt er substituert med en oksogruppe, eller Y er en gruppe (CH2)jO hvor oksygenatomet står nærmest gruppen X, og j er 2, 3 eller 4; og Z betegner en 5-leddet eller 6-leddet heteroaromatisk ring som eventuelt er substituert; samt farmasøytiske prepa- rater inneholdende disse forbindelser, deres anvendelse ved behandlingsmeto- -Y-X (D der, og deres anvendelse for fremstil- ling av preparater for forbedring av kognisjonen, spesielt ved Alzheimers sykdom, og tilsvarende behandlingsme- toder. Forbindelsene er ligander og invers-agonister for GABAA-a5-reseptor- subtypen.
NO20022456A 1999-11-25 2002-05-24 Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon NO20022456L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9927874.9A GB9927874D0 (en) 1999-11-25 1999-11-25 Therapeutic agents
GB0009602A GB0009602D0 (en) 2000-04-18 2000-04-18 Therapeutic agents
GB0018651A GB0018651D0 (en) 2000-07-28 2000-07-28 Therapeutic agents
PCT/GB2000/004450 WO2001038331A2 (en) 1999-11-25 2000-11-22 Pyrazolo[1,5-d][1,2,4]triazines for enhancing cognition

Publications (2)

Publication Number Publication Date
NO20022456D0 NO20022456D0 (no) 2002-05-24
NO20022456L true NO20022456L (no) 2002-05-24

Family

ID=27255677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022456A NO20022456L (no) 1999-11-25 2002-05-24 Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon

Country Status (20)

Country Link
US (1) US6355638B1 (no)
EP (1) EP1235829A2 (no)
JP (1) JP2003514909A (no)
KR (1) KR20020053091A (no)
CN (1) CN1391574A (no)
AU (1) AU1533001A (no)
BG (1) BG106734A (no)
BR (1) BR0015126A (no)
CA (1) CA2391103A1 (no)
CZ (1) CZ20021813A3 (no)
EA (1) EA200200599A1 (no)
EE (1) EE200200260A (no)
HK (1) HK1046406A1 (no)
HU (1) HUP0203579A3 (no)
IL (1) IL149051A0 (no)
MX (1) MXPA02005233A (no)
NO (1) NO20022456L (no)
PL (1) PL355637A1 (no)
SK (1) SK8952002A3 (no)
WO (1) WO2001038331A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
EP2298296A1 (en) * 2009-08-25 2011-03-23 CNRS Centre National De La Recherche Scientifique Composition and method for treating cognitive impairments in down syndrome subjects
AU2011258217B2 (en) * 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN107344936B (zh) * 2016-05-06 2022-06-03 上海赛默罗生物科技有限公司 ***哒嗪类衍生物、其制备方法、药物组合物和用途
CN107344938B (zh) * 2016-05-06 2022-05-06 上海赛默罗生物科技有限公司 吡唑-三嗪类衍生物、其制备方法、药物组合物和用途
CA3143334A1 (en) * 2019-06-19 2020-12-24 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710729A (pt) * 1996-07-25 1999-08-17 Merck Sharp & Dohme Composto composi-Æo farmac-utica utiliza-Æo de um composto e processo para o tratamento e/ou a preven-Æo da ansiedade e de convuls{es para a triagem de compostos ansioliticos nÆo-sedativos e para a prepara-Æo de um composto
GB9715977D0 (en) * 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
US6303597B1 (en) * 1998-01-14 2001-10-16 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
GB9806102D0 (en) * 1998-03-20 1998-05-20 Merck Sharp & Dohme Therapeutic agents
EP1087968A1 (en) * 1998-06-16 2001-04-04 MERCK SHARP & DOHME LTD. Triazolo-pyridine derivatives as ligands for gaba receptors
ES2291043T3 (es) * 1998-10-16 2008-02-16 MERCK SHARP & DOHME LIMITED Derivados de pirazolotriazina como ligandos para receptores de gaba.

Also Published As

Publication number Publication date
SK8952002A3 (en) 2002-10-08
EP1235829A2 (en) 2002-09-04
AU1533001A (en) 2001-06-04
BG106734A (en) 2003-02-28
HK1046406A1 (zh) 2003-01-10
IL149051A0 (en) 2002-11-10
NO20022456D0 (no) 2002-05-24
MXPA02005233A (es) 2002-11-07
PL355637A1 (en) 2004-05-04
WO2001038331A3 (en) 2001-11-08
KR20020053091A (ko) 2002-07-04
CZ20021813A3 (cs) 2002-08-14
CN1391574A (zh) 2003-01-15
HUP0203579A3 (en) 2003-07-28
HUP0203579A2 (hu) 2003-03-28
EA200200599A1 (ru) 2002-12-26
WO2001038331A2 (en) 2001-05-31
CA2391103A1 (en) 2001-05-31
US6355638B1 (en) 2002-03-12
EE200200260A (et) 2003-06-16
JP2003514909A (ja) 2003-04-22
BR0015126A (pt) 2002-07-02

Similar Documents

Publication Publication Date Title
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
EA200601235A1 (ru) Производные тиазола
HUP0300846A2 (hu) Imidazopirimidin- és triazolopirimidin-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
FI945900A0 (fi) Bentseenisulfonamidijohdokset ja menetelmä näiden valmistamiseksi
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
ATE452880T1 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
HUP9902340A2 (hu) Kondenzált piridinek és pirimidinek aril-amino-származékai, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények, továbbá e vegyületek alkalmazása
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
ES8802518A1 (es) Un procedimiento para preparar derivados de isoxazol y furano.
ATE74132T1 (de) Imid-derivate, ihre herstellung und ihre verwendung.
BR0015195A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
NO981241L (no) Heteroarylsubstituerte akryloylguanidinderivater og farmas÷ytiske preparater inneholdende disse
NO20022456L (no) Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon
ATE92489T1 (de) Imid-derivate, ihre herstellung und verwendung.
AU7810787A (en) 6-{2-(3-phenoxy-2-hydroxy-propylamino)-propyl-amino}-5- methyl-pyrizine-3-one derivatives useful as antihyper- tensive agents
BR0213177A (pt) Derivados de 5-metóxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
NO20051833L (no) 4-(3,5-dicyanofenoksy)pyrazolderivater for anvendelse som transkriptasemodulatorer ved behandling av IA HIV.
ATE325790T1 (de) Harnstoff-verbindungen, ein verfahren zu deren herstellung und ihre verwendung
DE69017855D1 (de) Oxetan-Derivate, ihre Herstellung und ihre Verwendung als Anti-Fungal oder fungizides Mittel.
EP0299076A4 (en) 5-hydroxyindole-3-carboxamide compound and medicinal use thereof
ES2053580T3 (es) Derivados de pirido(4,3-d)pirimidina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application